Phosphodiesterase 7A: A new therapeutic target for alleviating chronic inflammation?

Current Pharmaceutical Design

Volumn 12, Issue 25, 2006, Pages 3207-3220

  Giembycz, M A ^a,b   Smith, S J ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Asthma; cAMP; Chronic inflammation; COPD; Phosphodiesterase 7; Therapeutic target

Indexed keywords

1 [(3,4 DICHLOROPHENYL)METHYL] 2 ,1,3 BENZOTHIADIAZIN 4(3H) ONE 2,2 DIOXIDE; 1 [(4 BIPHENYL)CARBONYLMETHYL]BENZOTHIENO[3,2 A] 1,2,6 THIADIAZIN 4(3H) ONE 2,2 DIOXIDE; 1 [(4 METHOXYPHENYL)CARBONYLMETHYL]BENZOTHIENO[3,2 A] 1,2,6 THIADIAZIN 4(3H) ONE 2,2 DIOXIDE; 2 [4 [6,7 DIETHOXY 2,3 BIS(HYDROXYMETHYL) 1 NAPHTHYL] 2 PYRIDYL] 4 (3 PYRIDYL) 1(2H) PHTHALAZINONE; 2 METHYL 5 NITROBENZENESULFONIC ACID DIMETHYLAMIDE; BMS 586353; CYCLIC AMP; ESTERASE INHIBITOR; GUANINE DERIVATIVE; IC 242; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; PHOSPHODIESTERASE VIIA; PHOSPHODIESTERASE VIIA INHIBITOR; SULFONAMIDE; THIADIAZINE DERIVATIVE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIINFLAMMATORY ACTIVITY; ASTHMA; ATOPIC DERMATITIS; CHRONIC INFLAMMATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG INDUSTRY; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; GENE EXPRESSION REGULATION; GENE STRUCTURE; GENETIC VARIABILITY; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATORY CELL; LUPUS VULGARIS; MEDICAL LITERATURE; MOUSE; MULTIPLE SCLEROSIS; NAUSEA AND VOMITING; NONHUMAN; NUCLEOTIDE SEQUENCE; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SEQUENCE ALIGNMENT; SPECIES DIFFERENCE;

3',5'-CYCLIC-AMP PHOSPHODIESTERASES; 3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; AMINO ACID SEQUENCE; ANIMALS; ANTI-INFLAMMATORY AGENTS; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 7; DRUG DELIVERY SYSTEMS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MOLECULAR SEQUENCE DATA; PHOSPHODIESTERASE INHIBITORS;

EID: 33748529283     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206778194123     Document Type: Review

References (81)

1. Butcher RW, Sutherland EW. Adenosine 3′, 5′-phosphate in biological materials. I. Purification and properties of cyclic 3′, 5′-nucleotide phosphodiesterase and use of this enzyme to characterize adenosine 3′, 5′-phosphate in human urine. J Biol Chem 1962; 237: 1244-50.
2. Soderling SH, Bayuga SJ, Beavo JA. Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases. J Biol Chem 1998; 273: 15553-8.
3. Beavo JA. Multiple isozymes of cyclic nucleotide phosphodiesterase. Adv Second Messenger Phosphoprotein Res 1988; 22: 1-38.
4. Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 1995; 75: 725-48.
5. Conti M, Jin SL. The molecular biology of cyclic nucleotide phosphodiesterases. Prog Nucleic Acid Res Mol Biol 1999; 63: 1-38.
6. Torphy TJ. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 1998; 157: 351-70.
7. Giembycz MA. Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 2001; 10: 1361-79.
8. Huang Z, Ducharme Y, MacDonald D, Robichaud A. The next generation of PDE4 inhibitors. Curr Opin Chem Biol 2001; 5: 432-8.
9. Doherty AM. Phosphodiesterase 4 inhibitors as novel anti-inflammatory agents. Curr Opin Chem Biol 1999; 3: 466-73.
10. Souness JE, Aldous D, Sargent C. Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. Immunopharmacology 2000; 47: 127-62.
11. Dyke HJ, Montana JG. Update on the therapeutic potential of PDE4 inhibitors. Expert Opin Investig Drugs 2002; 11: 1-13.
12. Burnouf C, Pruniaux MP. Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs. Curr Pharm Des 2002; 8: 1255-96.
13. Giembycz MA. Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here? Drugs 2000; 59: 193-212.
14. 3H]rolipram binding activity and their relationship to emetic behavior in the ferret. J Med Chem 1996; 39: 120-5.
15. Souness JE, Rao S. Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases. Cell Signal 1997; 9: 227-36.
16. Compton CH, Gubb J, Nieman R, Edelson J, Amit O, Bakst A, et al. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. Lancet 2001; 358: 265-70.
17. Torphy TJ, Barnette MS, Underwood DC, Griswold DE, Christensen SB, Murdoch RD, et al. Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic. Pulm Pharmacol Ther 1999; 12: 131-5.
18. Giembycz MA. Development status of second generation PDE4 inhibitors for asthma and COPD: the story so far. Monaldi Arch Chest Dis 2002; 57: 48-64.
19. Michaeli T, Bloom TJ, Martins T, Loughney K, Ferguson K, Riggs M, et al. Isolation and characterization of a previously undetected human cAMP phosphodiesterase by complementation of cAMP phosphodiesterase-deficient Saccharomyces cerevisiae. J Biol Chem 1993; 268: 12925-32.
20. Ichimura M, Kase H. A new cyclic nucleotide phosphodiesterase isozyme expressed in the T-lymphocyte cell lines. Biochem Biophys Res Commun 1993; 193: 985-90.
21. Bloom TJ, Beavo JA. Identification and tissue-specific expression of PDE7 phosphodiesterase splice variants. Proc Natl Acad Sci USA 1996; 93: 14188-92.
22. Hetman JM, Soderling SH, Glavas NA, Beavo JA. Cloning and characterization of PDE7B, a cAMP-specific phosphodiesterase. Proc Natl Acad Sci USA 2000; 97: 472-6.
23. Sasaki T, Kotera J, Yuasa K, Omori K. Identification of human PDE7B, a cAMP-specific phosphodiesterase. Biochem Biophys Res Commun 2000; 271: 575-83.
24. Hoffmann R, Abdel'Al S, Engels P. Differential distribution of rat PDE-7 mRNA in embryonic and adult rat brain. Cell Biochem Biophys 1998; 28: 103-13.
25. Sasaki T, Kotera J, Omori K. Novel alternative splice variants of rat phosphodiesterase 7B showing unique tissue-specific expression and phosphorylation. Biochem J 2002; 361: 211-20.
26. Han P, Fletcher CF, Copeland NG, Jenkins NA, Yaremko LM, Michaeli T. Assignment of the mouse Pde7A gene to the proximal region of chromosome 3 and of the human PDE7A gene to chromosome 8q13. Genomics 1998; 48: 275-6.
27. Milatovich A, Bolger G, Michaeli T, Francke U. Chromosome localizations of genes for five cAMP-specific phosphodiesterases in man and mouse. Somat Cell Mol Genet 1994; 20: 75-86.
28. Minassian BA, Lee JR, Herbrick JA, Huizenga J, Soder S, Mungall AJ, et al. Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy. Nat Genet 1998; 20: 171-4.
29. + channels causes epilepsy. Nature 1998; 396: 687-90.
30. Torras-Llort M, Azorin F. Functional characterization of the human phosphodiesterase 7A1 promoter. Biochem J 2003; 373: 835-43.
31. Glavas NA, Ostenson C, Schaefer JB, Vasta V, Beavo JA. T cell activation up-regulates cyclic nucleotide phosphodiesterases 8A1 and 7A3. Proc Natl Acad Sci USA 2001; 98: 6319-24.
32. Han P, Zhu X, Michaeli T. Alternative splicing of the high affinity cAMP-specific phosphodiesterase (PDE7A) mRNA in human skeletal muscle and heart. J Biol Chem 1997; 272: 16152-7.
33. Kasuya J, Liang SJ, Goko H, Park SH, Kato K, Xu ZD, et al. Cardiac type cGMP-inhibited phosphodiesterase (PDE3A) gene structure: similarity and difference to adipocyte type PDE3B gene. Biochem Biophys Res Commun 2000; 268: 827-34.
34. Niiya T, Osawa H, Onuma H, Suzuki Y, Taira M, Yamada K, et al. Activation of mouse phosphodiesterase 3B gene promoter by adipocyte differentiation in 3T3-L1 cells. FEBS Lett 2001; 505: 136-40.
35. Rena G, Begg F, Ross A, MacKenzie C, McPhee I, Campbell L, et al. Molecular cloning, genomic positioning, promoter identification, and characterization of the novel cyclic amp-specific phosphodiesterase PDE4A10. Mol Pharmacol 2001; 59: 996-1011.
36. Olsen AE, Bolger GB. Physical mapping and promoter structure of the murine cAMP-specific phosphodiesterase pde4a gene. Mamm Genome 2000; 11: 41-5.
37. Vicini E, Conti M. Characterization of an intronic promoter of a cyclic adenosine 3′, 5′-monophosphate (cAMP)-specific phosphodiesterase gene that confers hormone and cAMP inducibility. Mol Endocrinol 1997; 11: 839-50.
38. Le Jeune IR, Shepherd M, Van Heeke G, Houslay MD, Hall IP. Cyclic AMP-dependent transcriptional up-regulation of phosphodiesterase 4D5 in human airway smooth muscle cells. Identification and characterization of a novel PDE4D5 promoter. J Biol Chem 2002; 277: 35980-9.
39. Lin CS, Chow S, Lau A, Tu R, Lue TF. Human PDE5A gene encodes three PDE5 isoforms from two alternate promoters. Int J Impot Res 2002; 14: 15-24.
40. Lin CS, Chow S, Lau A, Tu R, Lue TF. Regulation of human PDE5A2 intronic promoter by cAMP and cGMP: identification of a critical Sp1-binding site. Biochem Biophys Res Commun 2001; 280: 693-9.
41. Lin CS, Chow S, Lau A, Tu R, Lue TF. Identification and regulation of human PDE5A gene promoter. Biochem Biophys Res Commun 2001; 280: 684-92.
42. Lin CS, Lau A, Tu R, Lue TF. Identification of three alternative first exons and an intronic promoter of human PDE5A gene. Biochem Biophys Res Commun 2000; 268: 596-602.
43. Taylor RE, Shows KH, Zhao Y, Pittler SJ. A PDE6A promoter fragment directs transcription predominantly in the photoreceptor. Biochem Biophys Res Commun 2001; 282: 543-7.
44. 2-adrenoreceptor desensitization. J Biol Chem 1998; 273: 20575-88.
45. Lee R, Wolda S, Moon E, Esselstyn J, Hertel C, Lerner A. PDE7A is expressed in human B-lymphocytes and is up-regulated by elevation of intracellular cAMP. Cell Signal 2002; 14: 277-84.
46. Graef IA, Chen F, Crabtree GR. NFAT signaling in vertebrate development. Curr Opin Genet Dev 2001; 11: 505-12.
47. Macleod K, Leprince D, Stehelin D. The ets gene family. Trends Biochem Sci 1992; 17: 251-6.
48. Kontny E, Kurowska M, Szczepanska K, Maslinski W. Rottlerin, a PKC isozyme-selective inhibitor, affects signaling events and cytokine production in human monocytes. J Leukoc Biol 2000; 67: 249-58.
49. Miro X, Casacuberta JM, Gutierrez-Lopez MD, de Landazuri MO, Puigdomenech P. Phosphodiesterases 4D and 7A splice variants in the response of HUVEC cells to TNF-α. Biochem Biophys Res Commun 2000; 274: 415-21.
50. Li L, Yee C, Beavo JA. CD3- and CD28-dependent induction of PDE7 required for T cell activation. Science 1999; 283: 848-51.
51. + T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2. Br J Pharmacol 1996; 118: 1945-58.
52. Smith SJ, Brookes-Fazakerley S, Donnelly LE, Barnes PJ, Barnette MS, Giembycz MA. Ubiquitous expression of phosphodiesterase 7A in human proinflammatory and immune cells. Am J Physiol 2003; 294: L279-L289.
53. Gardner C, Robas N, Cawkill D, Fidock M. Cloning and characterization of the human and mouse PDE7B, a novel cAMP-specific cyclic nucleotide phosphodiesterase. Biochem Biophys Res Commun 2000; 272: 186-92.
54. Nemoz G, Zhang R, Sette C, Conti M. Identification of cyclic AMP-phosphodiesterase variants from the PDE4D gene expressed in human peripheral mononuclear cells. FEBS Lett 1996; 384: 97-102.
55. Richter W, Hermsdorf T, Kronbach T, Dettmer D. Refolding and purification of recombinant human PDE7A expressed in Escherichia coli as inclusion bodies. Protein Expr Purif 2002; 25: 138-48.
56. + T-lymphocytes. Mol Pharmacol 2004; 66: 1679-1689.
57. Wang P, Wu P, Egan RW, Billah MM. Cloning, characterization, and tissue distribution of mouse phosphodiesterase 7A1. Biochem Biophys Res Commun 2000; 276: 1271-7.
58. Martinez A, Castro A, Gil C, Miralpeix M, Segarra V, Domenech T, et al. Benzyl derivatives of 2, 1, 3-benzo- and benzothieno[3, 2-a]thiadiazine 2, 2-dioxides: first phosphodiesterase 7 inhibitors. J Med Chem 2000; 43: 683-9.
59. Castro A, Abasolo MI, Gil C, Segarra V, Martinez A. CoMFA of benzyl derivatives of 2, 1, 3-benzo and benzothieno[3, 2-alpha]thiadiazine 2, 2-dioxides: clues for the design of phosphodiesterase 7 inhibitors. Eur J Med Chem 2001; 36: 333-8.
60. PDE7 Inhibitors. Exp Opin Ther Patents 2004; 12: 601-3.
61. Barnes MJ, Cooper N, Davenport RJ, Dyke HJ, Galleway FP, Galvin FC, et al. Synthesis and structure-activity relationships of guanine analogues as phosphodiesterase 7 (PDE7) inhibitors. Bioorg Med Chem Lett 2001; 11: 1081-3.
62. Yang G, McIntyre KW, Townsend RM, Shen HH, Pitts WJ, Dodd JH, et al. Phosphodiesterase 7A-deficient mice have functional T cells. J Immunol 2003; 171: 6414-20.
63. Hatzelmann, A, Marx, D, Steinhilber, W. Phthalazinone derivatives useful as PDE4/7 inhibitors. 2004; WO 02/085906, Altana Pharma AG.
64. Eggenweiler H-M, Ackerman K-A, Jonas R, Wolf M, Gassen M, Welge T. Imidazopyridine derivatives as phosphodiesterase VII inhibitors. 2002; US 6, 613, 778, Merck Gmbh.
65. Eggenweiler H-M, Jonas R, Wolf M, Gassen M, Welge T. Imidazole compounds used as phosphodiesterase VII inhibitors. 2004; WO 01/36425, Merck Gmbh.
66. Pitts WJ, Watson AJ, Dodd JH. Dual inhibitors of PDE7 and PDE4. 2002; WO 02/088079, Bristol-Myers Squibb.
67. Vergne F, Ducrot P, Adrainjara C, Bernardelli P, Lorthiois E. New thiadiazoles and oxadiazoles and their use as phosphodiesterase-7 inhibitors. 2002; WO 02/28847, Warner-Lambert CO.
68. Nakata A, Ogawa K, Sasaki T, Koyama N, Wada K, Kotera J, et al. Potential role of phosphodiesterase 7 in human T cell function: comparative effects of two phosphodiesterase inhibitors. Clin Exp Immunol 2002; 128: 460-6.
69. Essayan DM, Kagey-Sobotka A, Lichtenstein LM, Huang SK. Differential regulation of human antigen-specific Th1 and Th2 lymphocyte responses by isozyme selective cyclic nucleotide phosphodiesterase inhibitors. J Pharmacol Exp Ther 1997; 282: 505-12.
70. Landells LJ, Szilagy CM, Jones NA, Banner KH, Allen JM, Doherty A, et al. Identification and quantification of phosphodiesterase 4 subtypes in CD4 and CD8 lymphocytes from healthy and asthmatic subjects. Br J Pharmacol 2001; 133: 722-9.
71. Staples KJ, Bergmann M, Tomita K, Houslay MD, McPhee I, Barnes PJ, et al. Adenosine 3′, 5′-cyclic monophosphate (cAMP)-dependent inhibition of IL-5 from human T lymphocytes is not mediated by the cAMP-dependent protein kinase A. J Immunol 2001; 167: 2074-80.
72. Jimenez JL, Punzon C, Navarro J, Munoz-Fernandez MA, Fresno M. Phosphodiesterase 4 inhibitors prevent cytokine secretion by T lymphocytes by inhibiting nuclear factor-κB and nuclear factor of activated T cells activation. J Pharmacol Exp Ther 2001; 299: 753-9.
73. Averill LE, Stein RL, Kammer GM. Control of human T-lymphocyte interleukin-2 production by a cAMP-dependent pathway. Cell Immunol 1988; 115: 88-99.
74. Robicsek SA, Blanchard DK, Djeu JY, Krzanowski JJ, Szentivanyi A, Polson JB. Multiple high-affinity cAMP-phosphodiesterases in human T-lymphocytes. Biochem Pharmacol 1991; 42: 869-77.
75. Stein CA. The experimental use of antisense oligonucleotides: a guide for the perplexed. J Clin Invest 2001; 108: 641-4.
76. Miro X, Perez-Torres S, Palacios JM, Puigdomenech P, Mengod G. Differential distribution of cAMP-specific phosphodiesterase 7A mRNA in rat brain and peripheral organs. Synapse 2001; 40: 201-14.
77. Perez-Torres S, Cortes R, Tolnay M, Probst A, Palacios JM, Mengod G. Alterations on phosphodiesterase type 7 and 8 isozyme mRNA expression in Alzheimer's disease brains examined by in situ hybridization. Exp Neurol 2003; 182: 322-34.
78. Barber R, Baillie GS, Bergmann R, Shepherd MC, Sepper R, Houslay MD, et al. Differential expression of PDE4 cyclic AMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and non-smokers. Am J Physiol 2004; 287: L332-L343.
79. Baldassarre G, Nicoloso MS, Schiappacassi M, Chimienti E, Belletti B. Linking inflammation to cell cycle progression. Curr Pharm Des 2004; 10(14): 1653-66.
80. Chen XL, Kunsch C. Induction of cytoprotective genes through Nrf2/ antioxidant response element pathway: a new therapeutic approach for the treatment of inflammatory diseases. Curr Pharm Des 2004; 10(8): 879-91.
81. Sin DD, Johnson M, Gan WQ, Man SF. Combination therapy of inhaled corticosteroids and long-acting beta2-adrenergics in management of patients with chronic obstructive pulmonary disease. Curr Pharm Des 2004; 10(28): 3547-60.